In conclusion, despite these limitations, we have demonstrated that TILs might serve as a robust marker for prognosticating the survival of patients with NSCLC, especially in TIL subtypes CD3+, CD4+, CD8+, and FoxP3+. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.